IAB2MA RPT / ImaginAb, Telix - LARVOL DELTA

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform (GlobeNewswire) - "Telix Pharmaceuticals Limited...announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities. This transaction delivers a pipeline of drug candidates against validated cancer targets including DLL3 and integrin αvβ6, as well as a panel of other agents against novel targets in early discovery stage. The Company believes that these next generation drug candidates fit synergistically with Telix’s therapeutics pipeline, enabling expansion to future therapy areas with unmet clinical need."

M&A • Solid Tumor